Member Info for Krone

Https://x.com/edison_inv_res/status/1910686880485593328?s=46

Good morning PCS,

Its probably safe to assume that SP has been lining up the SRA737 ducks since it became apparent that CPF were not intending to progress the target, i.e. back end of 2024. Assuming that the potential licensee/s have been given access to the data room the question would be how long does it take for experts to review said data and form a view on whether to bite the bullet. Also probably safe to assume that licensee/s will in parallel be conducting due diligence and discussing/agreeing terms with SP on the assumption that the data will support a deal.

The Edison reference to a 'strategic buyer' was I thought particularly intriguing!

Have a great weekend.

ATB

SDC-1801- We expect partnering discussions to gather speed in H2 CY25, as the drug progresses towards Phase II readiness.

SRA737 We believe Sareum will seek to out-license the asset to a strategic buyer, leveraging existing clinical data.

Https://www.edisongroup.com/research/broader-pipeline-bigger-milestones/BM-1503/

Wondering whether there is still potential value in Sareum’s FLT3 if the previously noted formulation issues can be addressed, perhaps by the application of AI tools. Clearly other FLT3 targets are being progressed.

https://aml-hub.com/medical-information/efficacy-and-safety-of-flt3-inhibitors-in-the-treatment-of-aml-a-review-of-clinical-data

Https://multiplesclerosisnewstoday.com/news-posts/2025/04/02/targeting-tyk2-brain-seen-potential-strategy-ms-treatment/

Good morning HBD,

Nice find!!

Clearly SRA737 still very much in play!!

ATB

Hi HBD,

I’d be entirely confident that SP will have carefully addressed all the potential issues that you flag before heralding the return of 737 to Sareum and the significant improvements in the economics. If it were to again stall significantly it wouldn’t look at all good!

ATB

Hi Celtic007,

IND (Investigational New Drug) approval is a critical regulatory milestone that allows a drug developer to begin human clinical trials in the U.S. under FDA oversight. It ensures that a new drug is safe enough to be tested in humans and that its proposed clinical trials are scientifically and ethically sound.

Significance of IND Approval

1. Legal Authorization for Human Trials

• Before IND approval, a drug can only be tested in preclinical studies (e.g., lab and animal models). IND approval grants FDA permission to begin clinical trials in humans.

2. Safety Assurance

• The FDA evaluates toxicology, pharmacology, and manufacturing data to ensure the drug does not pose undue risks to trial participants.

3. Establishes Trial Design Standards

• The IND application includes protocols for clinical trials, ensuring they are scientifically rigorous and ethically conducted.

4. Facilitates Investment and Partnerships

• Approval signals regulatory confidence, often helping companies attract investors, research collaborations, and pharmaceutical partnerships.

5. Enables Drug Development Pathway

• IND approval is a key step toward New Drug Application (NDA) or Biologics License Application (BLA) submission, which is required for final market approval.

Given the enormity of the Trump induced chaos within the FDA and related agencies it seems we have been incredibly fortunate in getting SRA737 back in house with an IND approval in place! G-d only knows how long it will take for new applications! Dr Parker has clearly grabbed this by the short and curlies and it’s certainly sounding very positive for rapid development!

https://x.com/lifescivc/status/1907083954815111467?s=46

Good morning C79,

Good to have you back!!

ATB

An interesting read.

https://www.edisongroup.com/insight/inside-the-mind-of-investors-oberon-investments/BM-1463/

Hybridan’s Comment:

We estimate a 15-month cash runway to progress the pipeline and clinical data. This should facilitate engagement with potential licensing and commercialisation partners at an enhanced value.

"Deucravacitinib is an oral, selective, allosteric TYK-2 inhibitor that is approved for the treatment of moderate to severe plaque psoriasis in the U.S. and other countries and is under investigation for the treatment of systemic lupus erythematosus (SLE), psoriatic arthritis and Sjögren’s disease".

https://www.healio.com/news/dermatology/20250317/deucravacitinib-improves-cutaneous-lupus-erythematosus-activity

Sareum's previous study with SRI International

'Novel Small-Molecule Inhibitor of Tyk2: Lucrative Therapeutic Target in Lupus'

https://apps.dtic.mil/sti/tr/pdf/AD1048482.pdf

Plenty of scope for dot joining!!

Good morning SOG,

Many thanks for such a comprehensive and interesting summary of your thoughts on SRA737 in the potential for treating pancreatic cancer. I suppose the key takeaway is that 737 has huge potential for treating a broad range of cancers and it is extremely positive that Dr Parker has has now flipped the target to Sareum's advantage!

ATB

Three months to the day since the CTR was reportedly received by the Board! Hopefully the paper for publication in a peer reviewed journal is well on the way and expecting to see an update on this in the half-year results. This could be the next significant value driver?

Morning HBD,

Thank you, that's very helpful.

In the last chance saloon any chance of effective treatment is surely priceless!

It is clear that SP has been driving this forward and the Linkedin reference was very encouraging in its overt optimism!

ATB

Includes references to Gemcitabine, SRA737 and combination therapy. Perhaps SOG or Citizen79 will summarise?

https://www.explorationpub.com/Journals/etat/Article/1002299

Https://www.linkedin.com/posts/sareum-ltd_today-we-are-delighted-to-announce-that-activity-7305968270061318144-uDKq?utm_source=share&utm_medium=member_ios&rcm=ACoAAD9qXvEBpRADMIIum0-eEcEOeU6YAq-gGEM

Https://x.com/edison_inv_res/status/1901612117909770411?s=46